• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[The Ras-related GTPase RhoB, a relevant actor in the adaptive resistance to EGFR tyrosine kinase inhibitors in lung cancers].

作者信息

Calvayrac Olivier, Pradines Anne, Mazières Julien, Favre Gilles

机构信息

Inserm U1037, centre de recherches en cancérologie de Toulouse, université Paul Sabatier, F-31057, Toulouse, France.

Inserm U1037, centre de recherches en cancérologie de Toulouse, université Paul Sabatier, F-31057, Toulouse, France - Institut Claudius Regaud, Institut universitaire du cancer-oncopole, F-31057, Toulouse, France.

出版信息

Med Sci (Paris). 2018 Jan;34(1):12-14. doi: 10.1051/medsci/20183401003. Epub 2018 Jan 31.

DOI:10.1051/medsci/20183401003
PMID:29384086
Abstract
摘要

相似文献

1
[The Ras-related GTPase RhoB, a relevant actor in the adaptive resistance to EGFR tyrosine kinase inhibitors in lung cancers].
Med Sci (Paris). 2018 Jan;34(1):12-14. doi: 10.1051/medsci/20183401003. Epub 2018 Jan 31.
2
[EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance].[表皮生长因子受体酪氨酸激酶抑制剂在肺癌治疗中的敏感性与耐药性]
Magy Onkol. 2012 Mar;56(1):38-49. Epub 2012 Jan 15.
3
The RAS-related GTPase RHOB confers resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer via an AKT-dependent mechanism.RAS相关的GTP酶RHOB通过一种AKT依赖性机制赋予非小细胞肺癌对表皮生长因子受体酪氨酸激酶抑制剂的抗性。
EMBO Mol Med. 2017 Feb;9(2):238-250. doi: 10.15252/emmm.201606646.
4
[Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma].[肺腺癌经表皮生长因子受体酪氨酸激酶抑制剂治疗后转化为小细胞肺癌的临床观察]
Zhongguo Fei Ai Za Zhi. 2015 Oct 20;18(10):656-60. doi: 10.3779/j.issn.1009-3419.2015.10.10.
5
Transformation to small cell lung cancer as an acquired resistance mechanism in EGFR-mutant lung adenocarcinoma: a case report of complete response to etoposide and cisplatin.表皮生长因子受体（EGFR）突变型肺腺癌中转化为小细胞肺癌作为一种获得性耐药机制：对依托泊苷和顺铂完全缓解的病例报告
Tumori. 2015 Jun 25;101(3):e96-8. doi: 10.5301/tj.5000276.
6
Drug Resistance to EGFR Inhibitors in Lung Cancer.肺癌对表皮生长因子受体抑制剂的耐药性
Chemotherapy. 2016;61(5):223-35. doi: 10.1159/000443368. Epub 2016 Feb 25.
7
Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma?血清神经元特异性烯醇化酶水平的快速升高和 EGFR 酪氨酸激酶抑制剂的耐药性表明，从 EGFR 阳性肺腺癌转化为小细胞肺癌？
Lung Cancer. 2013 Aug;81(2):302-5. doi: 10.1016/j.lungcan.2013.04.005. Epub 2013 May 15.
8
Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma.肺腺癌患者使用表皮生长因子受体酪氨酸激酶抑制剂治疗后转化为小细胞肺癌。
Lung Cancer. 2013 Nov;82(2):370-2. doi: 10.1016/j.lungcan.2013.06.003. Epub 2013 Sep 5.
9
Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.携带EGFR突变和EML4-ALK融合且受益于三种酪氨酸激酶抑制剂的肺腺癌：病例报告及文献综述
Clin Lung Cancer. 2015 Mar;16(2):e5-9. doi: 10.1016/j.cllc.2014.11.001. Epub 2014 Nov 18.
10
[Molecular Mechanism and Progression of Primary Resistance to EGFR-TKI
- Analysis of 2 Cases].[原发性EGFR-TKI耐药的分子机制与进展——2例分析]
Zhongguo Fei Ai Za Zhi. 2019 Jan 20;22(1):52-56. doi: 10.3779/j.issn.1009-3419.2019.01.10.